We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Patients are 266 percent more likely to not pick up brand-name medications after requesting them at a pharmacy, compared to generic prescriptions, according to the Association for Accessible Medicine’s annual report. Read More
The PTO’s Patent Trial and Appeal Board said it will review patents covering the blockbuster erectile dysfunction drug Cialis and a widely used pneumonia vaccine, Prevnar 13, granting petitions from Mylan and Merck Sharp & Dohme Corp. Read More
The PTO invalidated two more AbbVie patents on dosing regimens for Humira after continuing challenges from Coherus, which plans to submit its biosimilar version of the blockbuster drug for FDA approval later this year. Read More
The Senate Health, Education, Labor and Pensions Committee sought to answer basic questions on what is driving drug prices sky high, in a hearing ostensibly dedicated to the pharmaceutical industry — though it was frequently derailed by Democrats’ concerns over Republican efforts to repeal and replace the Affordable Care Act. Read More
In a case that may change how drug companies deal with patent infringement cases, the U.S. Supreme Court agreed to consider the constitutionality of the PTO’s inter partes review process, which allows the validity of patents to be challenged based on whether their claims are considered obvious at the time they are awarded. Read More
A pharmacy chain brought class action suits against 16 generics manufacturers — including Mylan, Sandoz, and Teva — claiming they conspired to raise prices of seven drugs, including blood pressure medications, antidepressants and corticosteroids. Read More
In a decision that reshapes the patent dance between biosimilar applicants and reference holders — and could affect the course of billions of dollars in the pharmaceutical industry — the U.S. Supreme Court ruled biosimilar manufacturers do not have to wait for FDA approval before beginning a six-month delay on commercial marketing. Read More
Years of legal wrangling came to a close with Allergan agreeing to a $13 million settlement for claims the company illegally promoted eye drugs by providing consulting and other services to doctors. Read More
Following the U.S. Supreme Court’s defining decision on the biosimilar “patent dance” and approval process, Sandoz has requested that an unresolved part of its case against Amgen return to a California federal district court. Read More
Following the U.S. Supreme Court’s defining decision on the biosimilar “patent dance” and approval process, Sandoz has requested that an unresolved part of its case against Amgen return to a California federal district court. Read More